Predicting Peripheral Neuropathy of Paclitaxel for Gastric Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age20+
SponsorCity of Hope Medical Center
About this trial
Although advances in chemotherapy have improved the prognosis of gastric cancer patients, many patients still suffer from adverse events. Therefore, it is necessary to establish personalized treatment by identifying patients at high risk for side effects. Although paclitaxel-based therapy is the standard second-line treatment, peripheral neuropathy is a troublesome adverse event. The purpose of this study is to establish a liquid biopsy assay to predict paclitaxel-induced peripheral neuropathy in gastric cancer patients.
Eligibility criteria
Qualifiers
unresectable or recurrent Gastric cancer (GC) histologically confirmed to be primary adenocarcinoma of the stomach.
age over 20 years.
Eastern Cooperative Oncology Group performance status score of 0-2.
written informed consent following full study information is provided to the patient.
Disqualifiers
Patients with a life expectancy of shorter than 3 months
Patients with severe complications (angina pectoris, myocardial infarction, or arrhythmia) or uncontrollable diabetes mellitus, blood hypertension, or bleeding tendency.
Patients with a history of serious allergic reactions or serious drug allergy.
Patients with a clinically relevant mental disorder that prohibits response to questionnaires.
Trial design
Treatments tested in this trial
- Paclitaxel
Treatment groups
150 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov